Profile data is unavailable for this security.
About the company
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
- Revenue in USD (TTM)2.00m
- Net income in USD-27.92m
- Incorporated2006
- Employees10.00
- LocationSagimet Biosciences Inc155 BOVET RD., SUITE 303SAN MATEO 94402United StatesUSA
- Phone+1 (650) 561-8600
- Fax+1 (302) 730-1370
- Websitehttps://sagimet.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hillevax Inc | 0.00 | -143.51m | 96.46m | 90.00 | -- | 0.3983 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 97.09m | 23.00 | -- | -- | -- | 1,427.79 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.50m | 99.15m | 68.00 | -- | 0.8587 | -- | -- | -1.86 | -1.86 | 0.00 | 1.75 | 0.00 | -- | -- | 0.00 | -66.79 | -- | -72.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -485.01m | 99.37m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 99.77m | 91.00 | -- | 0.7024 | -- | 3.21 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 104.36m | 10.00 | -- | 0.5492 | -- | 52.18 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 106.14m | 126.00 | -- | 0.8112 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 106.45m | 93.00 | -- | 2.57 | -- | 21.55 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.06m | -29.36m | 106.60m | 39.00 | -- | 0.9317 | -- | 100.19 | -2.12 | -2.12 | 0.055 | 4.23 | 0.0147 | -- | -- | 27,282.05 | -40.57 | -62.84 | -43.48 | -68.03 | -- | -- | -2,759.59 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 106.85m | 15.00 | 10.57 | 0.6395 | 10.23 | 158.54 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 4.70m | -79.58m | 108.46m | 66.00 | -- | -- | -- | 23.08 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Cardiff Oncology Inc | 610.00k | -40.25m | 108.68m | 31.00 | -- | 1.78 | -- | 178.17 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 109.29m | 8.00 | -- | 3.24 | -- | 17.83 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| CytomX Therapeutics Inc | 119.18m | 16.53m | 112.20m | 120.00 | 7.28 | -- | 6.04 | 0.9415 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 113.91m | 28.00 | -- | 1.06 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 115.32m | 325.00 | -- | -- | -- | 0.821 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
Data as of Jul 24 2024. Currency figures normalised to Sagimet Biosciences Inc's reporting currency: US Dollar USD
38.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 31 Mar 2024 | 2.67m | 8.77% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 1.38m | 4.55% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.18m | 3.90% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.12m | 3.67% |
| Alyeska Investment Group LPas of 31 Mar 2024 | 1.10m | 3.61% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 1.03m | 3.40% |
| RTW Investments LPas of 31 Mar 2024 | 999.15k | 3.29% |
| PFM Health Sciences LPas of 31 Mar 2024 | 802.71k | 2.64% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 782.07k | 2.57% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 770.67k | 2.54% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
